CD274 and head and neck squamous cell carcinoma: Hence, the level of PD-L1 expression should be measured when certain ICIs, such as durvalumab and pembrolizumab, are prescribed in the second-line treatment of R/M HNSCC, whereas the use of nivolumab in this setting may be ignored as the present evidence indicates.